guidelines:
  1: CRUSADE_for_post-MI_bleeding_risk.v1
test_cases:
- id: CHF(0)-VasDisease(0)-DM(0)-Gender(M)-PCV(50%)-HR(65)-SysBP(125)-CC(135)
  input:
    1:
      gt0003|Signs of CHF at presentation: 0|local::at0016|No|
      gt0004|History of vascular disease: 0|local::at0018|No|
      gt0005|History of diabetes mellitus: 0|local::at0020|No|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 50,%
      gt0054|Heart rate: 65,/min
      gt0058|Systolic BP: 125,mm[Hg]
      gt0060|Creatinine clearance: 135,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 0|local::at0027|≤70 BPM|
      gt0012|Systolic BP score: 1|local::at0035|121-180 mmHg|
      gt0008|Hematocrit score: 0|local::at0022|≥40 %|
      gt0009|Creatinine clearance score: 0|local::at0040|>120 mL/min|
      gt0016|Total score: 1
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 0|local::at0004|Initiation of anti-thrombotic and invasive therapies is reasonable given a relatively low risk of major bleeding.|
      gt0062|Risk level: 0|local::at0009|Very low risk (3.1%)|

- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(50%)-HR(65)-SysBP(125)-CC(135)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 50,%
      gt0054|Heart rate: 65,/min
      gt0058|Systolic BP: 125,mm[Hg]
      gt0060|Creatinine clearance: 135,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 0|local::at0027|≤70 BPM|
      gt0012|Systolic BP score: 1|local::at0035|121-180 mmHg|
      gt0008|Hematocrit score: 0|local::at0022|≥40 %|
      gt0009|Creatinine clearance score: 0|local::at0040|>120 mL/min|
      gt0016|Total score: 20
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 0|local::at0004|Initiation of anti-thrombotic and invasive therapies is reasonable given a relatively low risk of major bleeding.|
      gt0062|Risk level: 0|local::at0009|Very low risk (3.1%)|

- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(38%)-HR(65)-SysBP(125)-CC(135)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 38,%
      gt0054|Heart rate: 65,/min
      gt0058|Systolic BP: 125,mm[Hg]
      gt0060|Creatinine clearance: 135,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 0|local::at0027|≤70 BPM|
      gt0012|Systolic BP score: 1|local::at0035|121-180 mmHg|
      gt0008|Hematocrit score: 2|local::at0023|37-39.9%|
      gt0009|Creatinine clearance score: 0|local::at0040|>120 mL/min|
      gt0016|Total score: 22
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 1|local::at0005|Initiation of anti-thrombotic and invasive therapies should be considered|
      gt0062|Risk level: 1|local::at0010|Low risk (5.5%)|

- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(35%)-HR(65)-SysBP(125)-CC(135)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 35,%
      gt0054|Heart rate: 65,/min
      gt0058|Systolic BP: 125,mm[Hg]
      gt0060|Creatinine clearance: 135,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 0|local::at0027|≤70 BPM|
      gt0012|Systolic BP score: 1|local::at0035|121-180 mmHg|
      gt0008|Hematocrit score: 3|local::at0024|34-36.9%|
      gt0009|Creatinine clearance score: 0|local::at0040|>120 mL/min|
      gt0016|Total score: 23
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 1|local::at0005|Initiation of anti-thrombotic and invasive therapies should be considered|
      gt0062|Risk level: 1|local::at0010|Low risk (5.5%)|

- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(32%)-HR(65)-SysBP(125)-CC(135)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 32,%
      gt0054|Heart rate: 65,/min
      gt0058|Systolic BP: 125,mm[Hg]
      gt0060|Creatinine clearance: 135,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 0|local::at0027|≤70 BPM|
      gt0012|Systolic BP score: 1|local::at0035|121-180 mmHg|
      gt0008|Hematocrit score: 7|local::at0025|31-33.9%|
      gt0009|Creatinine clearance score: 0|local::at0040|>120 mL/min|
      gt0016|Total score: 27
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 1|local::at0005|Initiation of anti-thrombotic and invasive therapies should be considered|
      gt0062|Risk level: 1|local::at0010|Low risk (5.5%)|

- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(28%)-HR(65)-SysBP(125)-CC(135)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 28,%
      gt0054|Heart rate: 65,/min
      gt0058|Systolic BP: 125,mm[Hg]
      gt0060|Creatinine clearance: 135,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 0|local::at0027|≤70 BPM|
      gt0012|Systolic BP score: 1|local::at0035|121-180 mmHg|
      gt0008|Hematocrit score: 9|local::at0026|<31%|
      gt0009|Creatinine clearance score: 0|local::at0040|>120 mL/min|
      gt0016|Total score: 29
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 1|local::at0005|Initiation of anti-thrombotic and invasive therapies should be considered|
      gt0062|Risk level: 1|local::at0010|Low risk (5.5%)|


- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(28%)-HR(75)-SysBP(125)-CC(135)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 28,%
      gt0054|Heart rate: 75,/min
      gt0058|Systolic BP: 125,mm[Hg]
      gt0060|Creatinine clearance: 135,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 1|local::at0028|71-80 BPM|
      gt0012|Systolic BP score: 1|local::at0035|121-180 mmHg|
      gt0008|Hematocrit score: 9|local::at0026|<31%|
      gt0009|Creatinine clearance score: 0|local::at0040|>120 mL/min|
      gt0016|Total score: 30
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 1|local::at0005|Initiation of anti-thrombotic and invasive therapies should be considered|
      gt0062|Risk level: 1|local::at0010|Low risk (5.5%)|


- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(28%)-HR(85)-SysBP(125)-CC(135)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 28,%
      gt0054|Heart rate: 85,/min
      gt0058|Systolic BP: 125,mm[Hg]
      gt0060|Creatinine clearance: 135,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 3|local::at0029|81-90 BPM|
      gt0012|Systolic BP score: 1|local::at0035|121-180 mmHg|
      gt0008|Hematocrit score: 9|local::at0026|<31%|
      gt0009|Creatinine clearance score: 0|local::at0040|>120 mL/min|
      gt0016|Total score: 32
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 2|local::at0006|Initiation of anti-thrombotic and invasive therapies should be considered.|
      gt0062|Risk level: 2|local::at0011|Moderate risk (8.5%) |



- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(28%)-HR(95)-SysBP(125)-CC(135)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 28,%
      gt0054|Heart rate: 95,/min
      gt0058|Systolic BP: 125,mm[Hg]
      gt0060|Creatinine clearance: 135,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 6|local::at0030|91-100 BPM|
      gt0012|Systolic BP score: 1|local::at0035|121-180 mmHg|
      gt0008|Hematocrit score: 9|local::at0026|<31%|
      gt0009|Creatinine clearance score: 0|local::at0040|>120 mL/min|
      gt0016|Total score: 35
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 2|local::at0006|Initiation of anti-thrombotic and invasive therapies should be considered.|
      gt0062|Risk level: 2|local::at0011|Moderate risk (8.5%) |

- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(28%)-HR(105)-SysBP(125)-CC(135)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 28,%
      gt0054|Heart rate: 105,/min
      gt0058|Systolic BP: 125,mm[Hg]
      gt0060|Creatinine clearance: 135,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 8|local::at0031|101-110 BPM|
      gt0012|Systolic BP score: 1|local::at0035|121-180 mmHg|
      gt0008|Hematocrit score: 9|local::at0026|<31%|
      gt0009|Creatinine clearance score: 0|local::at0040|>120 mL/min|
      gt0016|Total score: 37
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 2|local::at0006|Initiation of anti-thrombotic and invasive therapies should be considered.|
      gt0062|Risk level: 2|local::at0011|Moderate risk (8.5%) |

- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(28%)-HR(115)-SysBP(125)-CC(135)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 28,%
      gt0054|Heart rate: 115,/min
      gt0058|Systolic BP: 125,mm[Hg]
      gt0060|Creatinine clearance: 135,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 10|local::at0032|111-120 BPM|
      gt0012|Systolic BP score: 1|local::at0035|121-180 mmHg|
      gt0008|Hematocrit score: 9|local::at0026|<31%|
      gt0009|Creatinine clearance score: 0|local::at0040|>120 mL/min|
      gt0016|Total score: 39
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 2|local::at0006|Initiation of anti-thrombotic and invasive therapies should be considered.|
      gt0062|Risk level: 2|local::at0011|Moderate risk (8.5%) |


- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(28%)-HR(125)-SysBP(125)-CC(135)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 28,%
      gt0054|Heart rate: 125,/min
      gt0058|Systolic BP: 125,mm[Hg]
      gt0060|Creatinine clearance: 135,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 11|local::at0033|≥121 BPM|
      gt0012|Systolic BP score: 1|local::at0035|121-180 mmHg|
      gt0008|Hematocrit score: 9|local::at0026|<31%|
      gt0009|Creatinine clearance score: 0|local::at0040|>120 mL/min|
      gt0016|Total score: 40
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 2|local::at0006|Initiation of anti-thrombotic and invasive therapies should be considered.|
      gt0062|Risk level: 2|local::at0011|Moderate risk (8.5%) |

- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(28%)-HR(125)-SysBP(190)-CC(135)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 28,%
      gt0054|Heart rate: 125,/min
      gt0058|Systolic BP: 190,mm[Hg]
      gt0060|Creatinine clearance: 135,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 11|local::at0033|≥121 BPM|
      gt0012|Systolic BP score: 3|local::at0036|181-200 mmHg|
      gt0008|Hematocrit score: 9|local::at0026|<31%|
      gt0009|Creatinine clearance score: 0|local::at0040|>120 mL/min|
      gt0016|Total score: 42
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 3|local::at0007|Judicious use of anti-thrombotic and invasive therapies is prudent in this high risk of bleeding group.|
      gt0062|Risk level: 3|local::at0012|High risk (11.9%)|


- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(28%)-HR(125)-SysBP(115)-CC(135)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 28,%
      gt0054|Heart rate: 125,/min
      gt0058|Systolic BP: 115,mm[Hg]
      gt0060|Creatinine clearance: 135,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 11|local::at0033|≥121 BPM|
      gt0012|Systolic BP score: 5|local::at0037|101-120 or ≥ 201mmHg|
      gt0008|Hematocrit score: 9|local::at0026|<31%|
      gt0009|Creatinine clearance score: 0|local::at0040|>120 mL/min|
      gt0016|Total score: 44
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 3|local::at0007|Judicious use of anti-thrombotic and invasive therapies is prudent in this high risk of bleeding group.|
      gt0062|Risk level: 3|local::at0012|High risk (11.9%)|


- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(28%)-HR(125)-SysBP(95)-CC(135)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 28,%
      gt0054|Heart rate: 125,/min
      gt0058|Systolic BP: 95,mm[Hg]
      gt0060|Creatinine clearance: 135,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 11|local::at0033|≥121 BPM|
      gt0012|Systolic BP score: 8|local::at0038|91–100 mmHg|
      gt0008|Hematocrit score: 9|local::at0026|<31%|
      gt0009|Creatinine clearance score: 0|local::at0040|>120 mL/min|
      gt0016|Total score: 47
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 3|local::at0007|Judicious use of anti-thrombotic and invasive therapies is prudent in this high risk of bleeding group.|
      gt0062|Risk level: 3|local::at0012|High risk (11.9%)|


- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(28%)-HR(125)-SysBP(80)-CC(135)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 28,%
      gt0054|Heart rate: 125,/min
      gt0058|Systolic BP: 80,mm[Hg]
      gt0060|Creatinine clearance: 135,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 11|local::at0033|≥121 BPM|
      gt0012|Systolic BP score: 10|local::at0039|≤90 mmHg|
      gt0008|Hematocrit score: 9|local::at0026|<31%|
      gt0009|Creatinine clearance score: 0|local::at0040|>120 mL/min|
      gt0016|Total score: 49
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 3|local::at0007|Judicious use of anti-thrombotic and invasive therapies is prudent in this high risk of bleeding group.|
      gt0062|Risk level: 3|local::at0012|High risk (11.9%)|

- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(28%)-HR(125)-SysBP(80)-CC(100)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 28,%
      gt0054|Heart rate: 125,/min
      gt0058|Systolic BP: 80,mm[Hg]
      gt0060|Creatinine clearance: 100,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 11|local::at0033|≥121 BPM|
      gt0012|Systolic BP score: 10|local::at0039|≤90 mmHg|
      gt0008|Hematocrit score: 9|local::at0026|<31%|
      gt0009|Creatinine clearance score: 7|local::at0041|>90-120mL/min|
      gt0016|Total score: 56
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 4|local::at0008|Judicious use of anti-thrombotic and invasive therapies is prudent in this very high risk of bleeding group.|
      gt0062|Risk level: 4|local::at0014|Very high risk (19.5%)|


- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(28%)-HR(125)-SysBP(80)-CC(70)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 28,%
      gt0054|Heart rate: 125,/min
      gt0058|Systolic BP: 80,mm[Hg]
      gt0060|Creatinine clearance: 70,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 11|local::at0033|≥121 BPM|
      gt0012|Systolic BP score: 10|local::at0039|≤90 mmHg|
      gt0008|Hematocrit score: 9|local::at0026|<31%|
      gt0009|Creatinine clearance score: 17|local::at0042|>60-90 mL/min|
      gt0016|Total score: 66
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 4|local::at0008|Judicious use of anti-thrombotic and invasive therapies is prudent in this very high risk of bleeding group.|
      gt0062|Risk level: 4|local::at0014|Very high risk (19.5%)|


- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(28%)-HR(125)-SysBP(80)-CC(40)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 28,%
      gt0054|Heart rate: 125,/min
      gt0058|Systolic BP: 80,mm[Hg]
      gt0060|Creatinine clearance: 40,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 11|local::at0033|≥121 BPM|
      gt0012|Systolic BP score: 10|local::at0039|≤90 mmHg|
      gt0008|Hematocrit score: 9|local::at0026|<31%|
      gt0009|Creatinine clearance score: 28|local::at0043|>30-60 mL/min|
      gt0016|Total score: 77
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 4|local::at0008|Judicious use of anti-thrombotic and invasive therapies is prudent in this very high risk of bleeding group.|
      gt0062|Risk level: 4|local::at0014|Very high risk (19.5%)|


- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(28%)-HR(125)-SysBP(80)-CC(20)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 28,%
      gt0054|Heart rate: 125,/min
      gt0058|Systolic BP: 80,mm[Hg]
      gt0060|Creatinine clearance: 20,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 11|local::at0033|≥121 BPM|
      gt0012|Systolic BP score: 10|local::at0039|≤90 mmHg|
      gt0008|Hematocrit score: 9|local::at0026|<31%|
      gt0009|Creatinine clearance score: 35|local::at0044|>15-30 mL/min|
      gt0016|Total score: 84
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 4|local::at0008|Judicious use of anti-thrombotic and invasive therapies is prudent in this very high risk of bleeding group.|
      gt0062|Risk level: 4|local::at0014|Very high risk (19.5%)|


- id: CHF(7)-VasDisease(6)-DM(6)-Gender(M)-PCV(28%)-HR(125)-SysBP(80)-CC(10)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0005|Male|
      gt0052|Packed cell volume (PCV): 28,%
      gt0054|Heart rate: 125,/min
      gt0058|Systolic BP: 80,mm[Hg]
      gt0060|Creatinine clearance: 10,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 11|local::at0033|≥121 BPM|
      gt0012|Systolic BP score: 10|local::at0039|≤90 mmHg|
      gt0008|Hematocrit score: 9|local::at0026|<31%|
      gt0009|Creatinine clearance score: 39|local::at0045|≤15 mL/min|
      gt0016|Total score: 88
      gt0010|Gender score: 0|local::at0014|Male|
      gt0063|Recommendation: 4|local::at0008|Judicious use of anti-thrombotic and invasive therapies is prudent in this very high risk of bleeding group.|
      gt0062|Risk level: 4|local::at0014|Very high risk (19.5%)|


- id: CHF(0)-VasDisease(0)-DM(0)-Gender(F)-PCV(50%)-HR(75)-SysBP(120)-CC(135)
  input:
    1:
      gt0003|Signs of CHF at presentation: 0|local::at0016|No|
      gt0004|History of vascular disease: 0|local::at0018|No|
      gt0005|History of diabetes mellitus: 0|local::at0020|No|
      gt0050|Gender: local::at0006|Female|
      gt0052|Packed cell volume (PCV): 50,%
      gt0054|Heart rate: 75,/min
      gt0058|Systolic BP: 120,mm[Hg]
      gt0060|Creatinine clearance: 135,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 1|local::at0028|71-80 BPM|
      gt0012|Systolic BP score: 5|local::at0037|101-120 or ≥ 201mmHg|
      gt0008|Hematocrit score: 0|local::at0022|≥40 %|
      gt0009|Creatinine clearance score: 0|local::at0040|>120 mL/min|
      gt0016|Total score: 14
      gt0010|Gender score: 8|local::at0015|Female|
      gt0063|Recommendation: 0|local::at0004|Initiation of anti-thrombotic and invasive therapies is reasonable given a relatively low risk of major bleeding.|
      gt0062|Risk level: 0|local::at0009|Very low risk (3.1%)|

- id: CHF(7)-VasDisease(6)-DM(6)-Gender(F)-PCV(28%)-HR(125)-SysBP(80)-CC(10)
  input:
    1:
      gt0003|Signs of CHF at presentation: 7|local::at0017|Yes|
      gt0004|History of vascular disease: 6|local::at0019|Yes|
      gt0005|History of diabetes mellitus: 6|local::at0021|Yes|
      gt0050|Gender: local::at0006|Female|
      gt0052|Packed cell volume (PCV): 28,%
      gt0054|Heart rate: 125,/min
      gt0058|Systolic BP: 80,mm[Hg]
      gt0060|Creatinine clearance: 10,ml/min
  expected_output:
    1:
      gt0007|Heart rate score: 11|local::at0033|≥121 BPM|
      gt0012|Systolic BP score: 10|local::at0039|≤90 mmHg|
      gt0008|Hematocrit score: 9|local::at0026|<31%|
      gt0009|Creatinine clearance score: 39|local::at0045|≤15 mL/min|
      gt0016|Total score: 96
      gt0010|Gender score: 8|local::at0015|Female|
      gt0063|Recommendation: 4|local::at0008|Judicious use of anti-thrombotic and invasive therapies is prudent in this very high risk of bleeding group.|
      gt0062|Risk level: 4|local::at0014|Very high risk (19.5%)|
